Varenicline is a partial α4β2 nicotinic acetylcholine receptor (nAChR) agonist originally prescribed for nicotine dependence. Because of the comorbid reward pathways between nicotine use disorder and alcohol use disorder, Varenicline sems promising as a potential treatment route for AUD. The gene discussed is CHRNA4; the disease is alcohol abuse.